Clozapine has a lower incidence of neurologic side effects, in particular extrapyramidal symptoms and is associated with a decreased mortality, largely due to a significant reduction in the risk of suicide, in comparison to firstgeneration antipsychotics. Favourable clinical results however are faced with a not negligible risk of serious adverse effects in particular agranulocytosis, weight gain or metabolic syndrome. Dilated cardiomyopathy, myocarditis, pericarditis and sudden death are less frequent but potentially fatal cardiac adverse effects related to clozapine treatment. The diagnosis of cardiac toxicity is usually made only when severe clinical symptoms occurs and impairment of left ventricular function is often irreversible At present no prospective studies on cardiac toxicity are reported in literature and clozapine related cardiac toxicity may be actually underestimated. In the present review we tried to up to date cardiovascular risk associated with clozapine treatment.
Keywords: Tumor Necrosis Factor, metabolic syndrome, Myocarditis, cardiomyopathy, necroscopy, corticosteroids, sarcoplasmatic, Drug resistant schizophrenia, clozapine, cardiotoxicity, dilated cardiomyopathy, PHARMACOLOGY, pericarditis, antipsychotics
Myocardial Quantitative Analysis in Physiological and Pathological Ventricular Hypertrophy: The Increasing Role of Doppler Myocardial Imaging
Current Cardiology Reviews The Role of Obesity in Cardiomyopathy and Nephropathy
Current Pharmaceutical Design Management of Chemotherapy Induced Cardiomyopathy
Current Cardiology Reviews Cellular Mechanisms for Diastolic Dysfunction in the Human Heart
Current Pharmaceutical Biotechnology Contemporary Treatment of Amyloid Heart Disease
Current Pharmaceutical Design The ACE2-Ang-(1-7)-Mas Axis and Cardioprotection
Current Cardiology Reviews Mitochondrial, Metabolic and Genotoxic Effects of Antiretroviral Nucleoside Reverse-Transcriptase Inhibitors
Anti-Infective Agents in Medicinal Chemistry Peripartum Cardiomyopathy: Moving Towards a More Central Role of Genetics
Current Cardiology Reviews How to Recognize Epicardial Origin of Ventricular Tachycardias?
Current Cardiology Reviews The Insular Cortex and Takotsubo Cardiomyopathy
Current Pharmaceutical Design Cross-Talk Between Adipose Tissue Health, Myocardial Metabolism and Vascular Function: The Adipose-Myocardial and Adipose-Vascular Axes
Current Pharmaceutical Design Human Myoblast Genome Therapies and Devices in Regenerative Medicine
Recent Patents on Regenerative Medicine (Discontinued) Adverse Cardiovascular Effects of Antirheumatic Drugs: Implications for Clinical Practice and Research
Current Pharmaceutical Design Pharmacological Approaches in the Treatment of Atrial Fibrillation
Current Medicinal Chemistry Editorial (Thematic Issue: Current Therapeutic Options in Cardiomyopathies)
Current Pharmaceutical Design Stage B: What is the Evidence for Treatment of Asymptomatic Left Ventricular Dysfunction?
Current Cardiology Reviews Occurrence and Clinical Impact of Microembolic Signals (MES) in Patients with Chronic Cardiac Diseases and Atheroaortic Plaques - A Systematic Review
Current Vascular Pharmacology Anthracycline-Induced Cardiotoxicity
Cardiovascular & Hematological Agents in Medicinal Chemistry Potential Therapeutic Targets in Cirrhotic Cardiomyopathy
Cardiovascular & Hematological Disorders-Drug Targets Oxidative stress and myocarditis
Current Pharmaceutical Design